FlexiOss® Ortho
Third-generation flexible bone substitute with TriCurean biphasic formula for orthopedic and traumatology procedures.
Modern implantable biomaterial — biphasic (hydroxyapatite-polymeric), bioactive, supporting bone tissue regeneration and a potential drug carrier. After implantation, it integrates with patient's bone and is slowly remodelled into natural bone tissue, eliminating reoperation.
Clinical Evidence
Product Demonstration
Hydration, moldability, and surgical handling of FlexiOss® Ortho
Clinical Video — Trauma Surgery
Live surgical application in comminuted fracture repair with FlexiOss® Ortho
PhilHealth Subsidy & Co-Payment Guide
Understand your PhilHealth subsidy allowance and co-payment options for procedures that use FlexiOss® — written for both patients and clinicians.
What Makes FlexiOss® Ortho Unique
Flexible After Soaking
Plastic and bendable — fits individual bone defects by cutting or bending during operation
Bio-Compatible
Compatible with natural bone tissue for seamless integration
Mechanical Parameters
Similar to those of cancellous bone — structural support
Supports Bone Reconstruction
Actively supports the bone reconstruction process
Absorbs Blood & Medicine
Absorbs blood and medicine solutions for enhanced drug delivery
Bone Tissue Regeneration
Positively affects bone tissue regeneration process
Ionic Reactive / Bioactive
High ionic reactivity increases mineralization rate
Non-Toxic Material
Thoroughly tested for safety — no cytotoxicity observed
Up to 7cm Defects
Can be used for bone defects of up to 7 cm in length
Non-Animal Material
Lowers risk of pathogen transmission and allergic reactions
Easy to Store & Transport
Simple storage and transportation requirements
Biphasic Formula
The combination of two main compounds was obtained by polymer gelling into an irreversible, collagen-like triple helix — a conformation which does not evoke local inflammation and enables the entrapment of HAP granulate.
Hydroxyapatite (HAP)
Ceramic Phase
Low-sintered, highly porous ceramic
Fully synthetic — high chemical stability
Supports regeneration via enhanced ion uptake
Most stable form of calcium phosphate
Curdlan Polymer
Polymeric Phase
Triple-helix structure (collagen-like)
Neutral for macrophages — no inflammation
Enables flexibility and high absorbency
Provides form stability
Clinical Applications
Comminuted fractures with bone tissue defects
Long bone defect filling and reconstruction (up to 5-7 cm)
Trauma surgery and emergency medicine
Bone pocket filling for tissue regeneration
Post-infective cyst removal and filling
Bone tumour resection defect reconstruction
Osteoporotic bone tissue fracture therapy
Bioactive filling of titanium and polyester scaffolds
Spinal fusion augmentation
Joint revision and arthrodesis procedures
Orthopaedics
Primary application area
Musculoskeletal Trauma
Emergency & reconstructive
Dentistry
Cyst & fistulae treatment
Veterinary
Companion animals
Certifications & Patents
CE Certified
EC No. 1434-MDD-269/2021
European conformity — highest safety standards
PH-FDA Approved
CMDR-2025-04943A
Certified for orthopedic applications in the Philippines
Patent Protected
European Patents
Protected across England, Austria, France, Spain, Ireland, Germany, Poland & Italy
FlexiOss® vs Leading Bone-Graft Products
Side-by-side against a PMMA bone cement, a hydroxyapatite ceramic and a β-TCP graft — every figure drawn from each manufacturer's own published documentation.
| Feature | FlexiOss® OrthoHAP + curdlan composite | Kyphon® Xpede™ / HV-R®Medtronic · PMMA cement | Bongros® HACGbio · HA ceramic | ExcelOs®CGbio / BioALPHA · β-TCP |
|---|---|---|---|---|
| Product form | Pre-formed sterile cylinder (double paper-foil pack) | Two-part cement — powder sachet + liquid bottle | Loose bone chips in jars | Granulate in jars |
| Available sizes | Ø13 mm cylinder — 1, 3 & 5 cm lengths | 20 g powder + 9 g liquid | Pre-filled granule jars (multiple volumes) | 0.3–0.6 mm (ortho) / 0.6–3.0 mm (dental); 5–30 cc |
| Composition | HAP granules (>100 nm) + curdlan sugar binder | Self-curing PMMA cement (MMA copolymer, barium sulphate, BPO) | Hydroxyapatite ceramic (mimics mineral bone) | 100% high-purity β-TCP |
| Resorbability | Resorbable HAP; curdlan degrades to glucose (metabolised) | — | — | 100% biodegradable — replaced by autograft |
| Animal / human tissue | None | None | None | None |
| Immunological / toxic reaction | None | — | — | — |
| Osseointegration | Excellent — osteoconductive scaffold; supports vascularization | — | Chemically fuses & grows into bone; preserves space for growth | Optimal osteoconduction; rapid bone in-growth |
| Porosity | Micro + macroporous; ~30 µm pores; 68–70% | — | 70–80% porous; ~300 µm pores | ~80% macroporosity; 100–300 µm pores |
| Absorption capacity | Absorbs blood/plasma → plastic, elastic & trimmable | — | — | — |
| X-ray visibility | Yes | Yes | — | — |
| Indications | Small & large defects — orthopedics, traumatology, dental & veterinary | Pathological vertebral fractures (kypho/vertebroplasty); tumours & metastases | Dental only — ridge augmentation, socket filling, sinus lift, periapical defects | Spine, joint revision, fracture repair, autograft extension, donor-site filler |
— indicates the specification was not stated in that product's published manufacturer documentation. Comparative information is sourced from manufacturer materials and provided for clinical reference.
FlexiOss® needs no special mixer or delivery device. PMMA cements cure exothermically — the local temperature spike can cause cell necrosis — and are prone to brittleness, depolymerisation, post-implant inflammation and reoperation from implant loosening. FlexiOss® avoids all of these.
FlexiOss® is a flexible, cut-to-size implant rather than loose, crumbly granules, and serves orthopedics, dentistry and veterinary use — whereas Bongros HA is dental-only. FlexiOss® Dent can even be used without a membrane and soaked in medication (e.g. metronidazole).
FlexiOss® is supplied as a moldable, trimmable cylinder that absorbs blood and plasma for single-step intra-operative application, rather than loose β-TCP granulate — and spans orthopedic, dental and veterinary indications.
Published Research
Characteristics and application of FlexiOss® bone substitute material in trauma-orthopedic patients
Lukasiewicz P.
Medical Inventi · 2025
Preliminary Results of Surgical Treatment for Enchondroma Using a Novel Bioactive and Osseoconductive HAP/β-Glucan Bone Substitute FlexiOss® — Case Series
Kotrych D., Ciechanowicz D., Bielewicz F., Baryluk A., Podsiadlo S., Zietek P.
J. Clin. Med. 2025, 14(11), 3738 · 2025
Behavior of new hydroxyapatite/glucan composite in human serum
Borkowski L., Lubek T., Jojczuk M., Nogalski A., Belcarz A., Palka K., Hajnos M., Ginalska G.
J. Biomed. Mater. Res. Part B., 2018, 106B(7), 2653-2664 · 2018
Unexpected reaction of new HAp/glucan composite to environmental acidification: Defect or advantage?
Borkowski L., Kiernicka M., Belcarz A., Palka K., Hajnos M., Ginalska G.
Biomed. Mater. Res. B Appl. Biomater. 2017, 105(5), 1178-1190 · 2017
The comparison study of bioactivity between composites containing synthetic non-substituted and carbonate-substituted hydroxyapatite
Borkowski L., Sroka-Bartnicka A., et al.
Mater. Sci. Eng. C Mater. Biol. Appl. 2016, 62, 260-267 · 2016
Biphasic mode of antibacterial action of aminoglycoside antibiotics-loaded elastic hydroxyapatite-glucan composite
Belcarz A., Zima A., Ginalska G.
Int. J. Pharm. 2013, 454, 285-295 · 2013
Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair
Belcarz A., Ginalska G., Pycka T., et al.
Centr. Eur. J. Biol. 2013, 8, 534-548 · 2013